Emergen Research's latest market research report, titled Global Drug and Gene Delivery Devices Market, provides estimated market size and shares, latest industry trends, global market growth rates, key drivers and opportunities, constraints, product segmentation, and major market players. Cost structure, market size, competitive landscape, product portfolio and specifications, and company profiles.

This report is a fair prototype of the Drug and Gene Delivery Devices-industry containing an in-depth study of the global Drug and Gene Delivery Devices market. This report serves as a valuable source of data and information related to this industry. It covers various industry aspects with a particular focus on market scope and application areas. The report identifies the fundamental business strategies adopted by industry experts and offers an insightful study on the value chains and distribution channels of the global market. The report authors have also analyzed current industry trends, growth potential, current overview, and market limitations.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4835

The Drug and Gene Delivery Devices market is expected to grow from an estimated USD 310.1 billion in 2024 to USD 510.7 billion in 2035, at a CAGR of 5.70%.

The growth of the Drug and Gene Delivery Devices Market is attributed to the rising incidence of genetic and chronic diseases, technological advancements in biotechnology and nanotechnology, and the increasing emphasis on personalized medicine. Furthermore, expanding investments in gene therapy research and the approval of gene-based treatments by regulatory authorities are driving market expansion. Approximately 90% of the nation’s $4.5 trillion in annual healthcare expenditures are allocated to managing chronic and mental health conditions.

Heart disease and stroke account for over 944,800 deaths annually in the United States, representing more than one-third of total deaths. Additionally, 1.7 million new cancer cases are diagnosed each year in the United States, with over 600,000 cancer-related deaths, positioning cancer as the second leading cause of mortality. The cost of cancer care is projected to exceed $240 billion by 2030.

According to the World Health Organization (WHO), chronic diseases are responsible for over 70% of global deaths, with a significant genetic component. Gene therapy has emerged as a viable treatment option for these diseases, driving the need for effective and efficient delivery systems to transport genetic material into targeted cells.

Advancements in biotechnology and nanotechnology have facilitated the development of innovative gene delivery platforms. Nanoparticles, liposomes, and viral vectors are increasingly utilized for gene delivery due to their high targeting efficiency and reduced toxicity. The introduction of CRISPR-Cas9 and other gene-editing technologies has heightened the demand for specialized delivery systems to enable precise delivery and effective gene editing. For instance, CRISPR-based therapies for sickle cell anemia and thalassemia require highly targeted delivery mechanisms to introduce corrective genes.

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Drug and Gene Delivery Devices market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Drug and Gene Delivery Devices market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Drug and Gene Delivery Devices market.

Market Segmentation:

The report bifurcates the Drug and Gene Delivery Devices market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment.

Market competition in the Drug and Gene Delivery Devices industry is characterized by the presence of global and regional players such as Uniqure N.V., SiBiono GeneTech Co., Epeius Biotechnologies Corporation, and others. Advancements in delivery platforms, including viral vectors, lipid nanoparticles, and CRISPR-based systems, are improving targeting precision and minimizing toxicity.

Regulatory support for gene therapies and drug delivery devices is facilitating faster market entry and wider adoption. Market participants are differentiating their offerings by enhancing targeting accuracy, improving safety profiles, and delivering sustained therapeutic benefits. The competitive landscape is expected to remain dynamic, shaped by ongoing industry consolidation, technological progress, and the entry of new market players.

In February 2024, UT Southwestern entered into a collaboration with Pfizer to develop advanced RNA delivery technologies. This partnership is anticipated to enhance the understanding of genetic medicine and expand AI-based design methodologies, supporting the development of novel delivery technologies for potential therapeutic applications.

• Uniqure N.V.
• SiBiono GeneTech Co.
• Epeius Biotechnologies Corporation
• Shanghai Sunway Biotech Co., Ltd
• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson and Johnson
• Novartis AG
• Bayer AG
• Becton, Dickinson and Company

Target Audience of the Global Drug and Gene Delivery Devices Market Report:

• Key Market Players
• Investors
• Venture capitalists
• Small- and medium-sized and large enterprises
• Third-party knowledge providers
• Value-Added Resellers (VARs)
• Global market producers, distributors, traders, and suppliers
• Research organizations, consulting companies, and various alliances interested in this sector
• Government bodies, independent regulatory authorities, and policymakers

• Oral
• Ocular
• Inhalation
• Nasal
• Injectable
• Transdermal
• Topical

• In Situ
• Ex Vivo

• Viral Vector
• Non-Viral Vector

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Turkey
  • Rest of MEA

• United States
• Canada
• Mexico

• Germany
• France
• United Kingdom
• Italy
• Spain
• Benelux
• Rest of Europe

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

• Brazil
• Rest of Latin America

• Saudi Arabia
• UAE
• South Africa
• Turkey
• Rest of MEA

Key Questions the Report Will Answer

• What was the market size of the Drug and Gene Delivery Devices market in 2024?
  • The Drug and Gene Delivery Devices market size in 2024 was USD 310.1 billion.
• What is the expected revenue Compound Annual Growth Rate (CAGR) of the Drug and Gene Delivery Devices market over the forecast period?
  • The Drug and Gene Delivery Devices market is expected to register a revenue Compound Annual Growth Rate (CAGR) of 5.70% over the forecast period.
• Which factors are expected to drive Drug and Gene Delivery Devices market revenue growth?
  • Rising Investments and Funding in Gene Therapy Research are expected to drive revenue growth of the global Drug and Gene Delivery Devices market.
• Which regional market is expected to account for the largest revenue share in the Drug and Gene Delivery Devices market?
  • The North America market is expected to account for the largest revenue share in the Drug and Gene Delivery Devices market over the forecast period.
• Which are some of the major companies included in the global Drug and Gene Delivery Devices market report?
• Some of the major companies in the global Drug and Gene Delivery Devices market include Uniqure N.V., SiBiono GeneTech Co., Epeius Biotechnologies Corporation, Shanghai Sunway Biotech Co., Ltd, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Johnson and Johnson, Novartis AG, Bayer AG, Becton, Dickinson and Company.

• The Drug and Gene Delivery Devices market size in 2024 was USD 310.1 billion.

• The Drug and Gene Delivery Devices market is expected to register a revenue Compound Annual Growth Rate (CAGR) of 5.70% over the forecast period.

• Rising Investments and Funding in Gene Therapy Research are expected to drive revenue growth of the global Drug and Gene Delivery Devices market.

• The North America market is expected to account for the largest revenue share in the Drug and Gene Delivery Devices market over the forecast period.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/drug-and-gene-delivery-devices-market

Competitive Terrain:

The global Drug and Gene Delivery Devices industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

Increased government and private sector funding for gene therapy research is fostering innovation in drug gene delivery technologies. The U.S. National Institutes of Health (NIH) and the European Union have allocated significant funds to support gene therapy research. Q2 2023 marked a notable period for approvals, with six new therapies approved—two each in the gene, cell, and RNA therapy categories. In Q1 2023, there were 247 gene therapies in Phase II trials, which increased by 5% to 260 by the end of Q2.

Pharmaceutical companies and biotech firms are also forming strategic partnerships to accelerate the development of drug gene delivery systems. In Q2 2023, 21 companies announced seed or Series A funding rounds, the highest quarterly figure in the past year, raising an aggregate of $1.3 billion—more than double the amount secured in Q1.

• Rising Investments and Funding in Gene Therapy Research

Key reasons to buy the Global Drug and Gene Delivery Devices Market report:

1. The latest report comprehensively studies the global Drug and Gene Delivery Devices market size and provides useful inference on numerous aspects of the market, such as the current business trends, market share, product offerings, and product share.
2. The report offers an insightful analysis of the regional outlook of the market.
3. It offers a detailed account of the end-use applications of the products & services offered by this industry.
4. The report holistically covers the latest developments taking place in this industry. Therefore, it lists the most effective business strategies implemented by the market rivals for ideal business expansion.

Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4835

Thank you for reading our report. For further details or to inquire about customization, please let us know and we will offer you the report as per your needs.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com